Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2007 4
2008 4
2009 4
2010 3
2011 6
2012 10
2013 7
2014 13
2015 30
2016 45
2017 40
2018 38
2019 37
2020 31
2021 31
2022 33
2023 49
2024 39
2025 23

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

393 results

Results by year

Filters applied: . Clear all
Page 1
Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019.
Global Burden of Disease 2019 Cancer Collaboration; Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, Harvey JD, Henrikson HJ, Lu D, Pennini A, Xu R, Ababneh E, Abbasi-Kangevari M, Abbastabar H, Abd-Elsalam SM, Abdoli A, Abedi A, Abidi H, Abolhassani H, Adedeji IA, Adnani QES, Advani SM, Afzal MS, Aghaali M, Ahinkorah BO, Ahmad S, Ahmad T, Ahmadi A, Ahmadi S, Ahmed Rashid T, Ahmed Salih Y, Akalu GT, Aklilu A, Akram T, Akunna CJ, Al Hamad H, Alahdab F, Al-Aly Z, Ali S, Alimohamadi Y, Alipour V, Aljunid SM, Alkhayyat M, Almasi-Hashiani A, Almasri NA, Al-Maweri SAA, Almustanyir S, Alonso N, Alvis-Guzman N, Amu H, Anbesu EW, Ancuceanu R, Ansari F, Ansari-Moghaddam A, Antwi MH, Anvari D, Anyasodor AE, Aqeel M, Arabloo J, Arab-Zozani M, Aremu O, Ariffin H, Aripov T, Arshad M, Artaman A, Arulappan J, Asemi Z, Asghari Jafarabadi M, Ashraf T, Atorkey P, Aujayeb A, Ausloos M, Awedew AF, Ayala Quintanilla BP, Ayenew T, Azab MA, Azadnajafabad S, Azari Jafari A, Azarian G, Azzam AY, Badiye AD, Bahadory S, Baig AA, Baker JL, Balakrishnan S, Banach M, Bärnighausen TW, Barone-Adesi F, Barra F, Barrow A, Behzadifar M, Belgaumi UI, Bezabhe WMM, Bezabih YM, Bhagat DS, Bhagavathula AS, Bhardwaj N, Bhard… See abstract for full author list ➔ Global Burden of Disease 2019 Cancer Collaboration, et al. JAMA Oncol. 2022 Mar 1;8(3):420-444. doi: 10.1001/jamaoncol.2021.6987. JAMA Oncol. 2022. PMID: 34967848 Free PMC article.
Global Burden of Cardiovascular Diseases and Risks, 1990-2022.
Mensah GA, Fuster V, Murray CJL, Roth GA; Global Burden of Cardiovascular Diseases and Risks Collaborators. Mensah GA, et al. J Am Coll Cardiol. 2023 Dec 19;82(25):2350-2473. doi: 10.1016/j.jacc.2023.11.007. J Am Coll Cardiol. 2023. PMID: 38092509 Free PMC article. No abstract available.
Cohort profile: golestan hepatitis B cohort study- a prospective long term study in northern iran .
Poustchi H, Katoonizadeh A, Ostovaneh MR, Moossavi S, Sharafkhah M, Esmaili S, Pourshams A, Mohamadkhani A, Besharat S, Merat S, Mohamadnejad M, George J, Malekzadeh R. Poustchi H, et al. Middle East J Dig Dis. 2014 Oct;6(4):186-94. Middle East J Dig Dis. 2014. PMID: 25349681 Free PMC article.
Hepatitis B virus (HBV) infection is the most common cause of end stage liver disease in Iran and in Golestan province. ...Moreover, the underlying molecular mechanisms and immunogenetic determinants of the outcome of HBV infection especially in low and middle incom …
Hepatitis B virus (HBV) infection is the most common cause of end stage liver disease in Iran and in Golestan province. ...Mor …
Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
Ardebili A, Izanloo A, Rastegar M. Ardebili A, et al. Expert Rev Anti Infect Ther. 2023 Apr;21(4):387-429. doi: 10.1080/14787210.2023.2184346. Epub 2023 Mar 8. Expert Rev Anti Infect Ther. 2023. PMID: 36820511 Review.
AREAS COVERED: The rapid growing of multi-resistant GNB as well as the considerable deceleration in development of new anti-infective agents have made polymyxins (e.g. polymyxin B and colistin) a mainstay in clinical practices as either monotherapy or combination therapy. …
AREAS COVERED: The rapid growing of multi-resistant GNB as well as the considerable deceleration in development of new anti-infective agents …
Prevalence of occult hepatitis B virus infection among the blood donors in Golestan province: cross-sectional study.
Bahrami A, Pourfathollah AA, Parsania M, Mehrabi Habibabadi H, Sharifi Z. Bahrami A, et al. Iran J Microbiol. 2022 Jun;14(3):410-416. doi: 10.18502/ijm.v14i3.9793. Iran J Microbiol. 2022. PMID: 37124850 Free PMC article.
BACKGROUND AND OBJECTIVES: Despite the increased sensitivity of screening tests, the HBV can be transmitted during the window period and occult hepatitis B infection. The purpose of this study was to evaluate HBV markers and prevalence of OBI among HBsAg negative blood don …
BACKGROUND AND OBJECTIVES: Despite the increased sensitivity of screening tests, the HBV can be transmitted during the window period and occ …
Mutational signatures in esophageal squamous cell carcinoma from eight countries with varying incidence.
Moody S, Senkin S, Islam SMA, Wang J, Nasrollahzadeh D, Cortez Cardoso Penha R, Fitzgerald S, Bergstrom EN, Atkins J, He Y, Khandekar A, Smith-Byrne K, Carreira C, Gaborieau V, Latimer C, Thomas E, Abnizova I, Bucciarelli PE, Jones D, Teague JW, Abedi-Ardekani B, Serra S, Scoazec JY, Saffar H, Azmoudeh-Ardalan F, Sotoudeh M, Nikmanesh A, Poustchi H, Niavarani A, Gharavi S, Eden M, Richman P, Campos LS, Fitzgerald RC, Ribeiro LF, Soares-Lima SC, Dzamalala C, Mmbaga BT, Shibata T, Menya D, Goldstein AM, Hu N, Malekzadeh R, Fazel A, McCormack V, McKay J, Perdomo S, Scelo G, Chanudet E, Humphreys L, Alexandrov LB, Brennan P, Stratton MR. Moody S, et al. Nat Genet. 2021 Nov;53(11):1553-1563. doi: 10.1038/s41588-021-00928-6. Epub 2021 Oct 18. Nat Genet. 2021. PMID: 34663923
We find no evidence of a mutational signature indicative of an exogenous exposure capable of explaining differences in ESCC incidence. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC)-associated mutational signatures single-base substitution (SBS)2 …
We find no evidence of a mutational signature indicative of an exogenous exposure capable of explaining differences in ESCC incidence. Apoli …
Biallelic human SHARPIN loss of function induces autoinflammation and immunodeficiency.
Oda H, Manthiram K, Chavan PP, Rieser E, Veli Ö, Kaya Ö, Rauch C, Nakabo S, Kuehn HS, Swart M, Wang Y, Çelik NI, Molitor A, Ziaee V, Movahedi N, Shahrooei M, Parvaneh N, Alipour-Olyei N, Carapito R, Xu Q, Preite S, Beck DB, Chae JJ, Nehrebecky M, Ombrello AK, Hoffmann P, Romeo T, Deuitch NT, Matthíasardóttir B, Mullikin J, Komarow H, Stoddard J, Niemela J, Dobbs K, Sweeney CL, Anderton H, Lawlor KE, Yoshitomi H, Yang D, Boehm M, Davis J, Mudd P, Randazzo D, Tsai WL, Gadina M, Kaplan MJ, Toguchida J, Mayer CT, Rosenzweig SD, Notarangelo LD, Iwai K, Silke J, Schwartzberg PL, Boisson B, Casanova JL, Bahram S, Rao AP, Peltzer N, Walczak H, Lalaoui N, Aksentijevich I, Kastner DL. Oda H, et al. Nat Immunol. 2024 May;25(5):764-777. doi: 10.1038/s41590-024-01817-w. Epub 2024 Apr 12. Nat Immunol. 2024. PMID: 38609546 Free PMC article.
Here, we report two individuals with SHARPIN deficiency who manifest autoinflammatory symptoms but unexpectedly no dermatological problems. Fibroblasts and B cells from these individuals showed attenuated canonical NF-kappaB responses and a propensity for cell death mediat …
Here, we report two individuals with SHARPIN deficiency who manifest autoinflammatory symptoms but unexpectedly no dermatological problems. …
Geographic and age variations in mutational processes in colorectal cancer.
Díaz-Gay M, Dos Santos W, Moody S, Kazachkova M, Abbasi A, Steele CD, Vangara R, Senkin S, Wang J, Fitzgerald S, Bergstrom EN, Khandekar A, Otlu B, Abedi-Ardekani B, de Carvalho AC, Cattiaux T, Penha RCC, Gaborieau V, Chopard P, Carreira C, Cheema S, Latimer C, Teague JW, Mukeriya A, Zaridze D, Cox R, Albert M, Phouthavongsy L, Gallinger S, Malekzadeh R, Niavarani A, Miladinov M, Erić K, Milosavljevic S, Sangrajrang S, Curado MP, Aguiar S, Reis RM, Reis MT, Romagnolo LG, Guimarães DP, Holcatova I, Kalvach J, Vaccaro CA, Piñero TA, Świątkowska B, Lissowska J, Roszkowska-Purska K, Huertas-Salgado A, Shibata T, Shiba S, Sangkhathat S, Chitapanarux T, Roshandel G, Ashton-Prolla P, Damin DC, de Oliveira FH, Humphreys L, Lawley TD, Perdomo S, Stratton MR, Brennan P, Alexandrov LB. Díaz-Gay M, et al. Nature. 2025 Jul;643(8070):230-240. doi: 10.1038/s41586-025-09025-8. Epub 2025 Apr 23. Nature. 2025. PMID: 40267983 Free PMC article.
An Overview of Hepatitis B Virus Surface Antigen Secretion Inhibitors.
Mohebbi A, Lorestani N, Tahamtan A, Kargar NL, Tabarraei A. Mohebbi A, et al. Front Microbiol. 2018 Apr 5;9:662. doi: 10.3389/fmicb.2018.00662. eCollection 2018. Front Microbiol. 2018. PMID: 29675010 Free PMC article. Review.
Current anti-hepatitis B virus (HBV) regimen do not meet ideal result due to emerging resistance strains, cytotoxicity, and unfavorable adverse effects. ...
Current anti-hepatitis B virus (HBV) regimen do not meet ideal result due to emerging resistance strains, cytotoxicity, and unfavorab …
393 results